

**Table 2. Treatment-Emergent Adverse Events (TEAEs)**

<b>TEAE</b>	<b>Number (%) of Patients</b>	
	<b>Concomitant Benzodiazepines Subgroup (n=119)</b>	<b>No Concomitant Benzodiazepines Subgroup (n=39)</b>
Any TEAE	95 (79.8)	24 (61.5)
Serious TEAE	36 (30.3)	9 (23.1)
Treatment-related TEAE	22 (18.5)	4 (10.3)
Most common TEAEs ( $\geq 5\%$ in either subgroup)		
Seizure	19 (16.0)	4 (10.3)
Pyrexia	10 (8.4)	0
Nasopharyngitis	11 (9.2)	1 (2.6)
Pneumonia	9 (7.6)	2 (5.1)
Nasal discomfort	8 (6.7)	1 (2.6)
Influenza	8 (6.7)	0
Upper respiratory tract infection	8 (6.7)	4 (10.3)
Urinary tract infection	7 (5.9)	0
Dizziness	5 (4.2)	2 (5.1)
Headache	6 (5.0)	1 (2.6)
Somnolence	4 (3.4)	3 (7.7)
Cough	2 (1.7)	2 (5.1)
Fatigue	0	2 (5.1)
Gastroesophageal reflux disease	0	2 (5.1)
Vomiting	5 (4.2)	2 (5.1)